Showing posts with label Clinical. Show all posts
Showing posts with label Clinical. Show all posts

Saturday, 27 July 2013

Fullest clinical report of Saudi MERS cases to date points to important differences with SARS

Main Category: Infectious Diseases / Bacteria / Viruses
Also Included In: Flu / Cold / SARS
Article Date: 26 Jul 2013 - 2:00 PDT Current ratings for:
Fullest clinical report of Saudi MERS cases to date points to important differences with SARS
not yet ratednot yet rated

Saudi and UK scientists provide the most detailed picture yet of the clinical and laboratory characteristics of Middle East Respiratory Syndrome (MERS) coronavirus, revealing a wide range of clinical symptoms and an extremely high death rate among patients with co-existing medical conditions.

The new research, published in The Lancet Infectious Diseases, also reveals some important differences with severe acute respiratory syndrome (SARS).

MERS emerged a year ago in Saudi Arabia and almost all those infected have been reported there, or have been linked to people who contracted the virus there.

The new analysis, the largest case series to date, includes 47 cases (46 adults, 1 child) of confirmed MERS infections from Saudi Arabia between Sept 1, 2012, and June 15, 2013.

By combining clinical records, laboratory results, and imaging findings with demographic data, the authors noted a trend of older patients, more men, and patients with underlying medical conditions who succumb to the disease.

As with SARS, MERS infections presented with a wide spectrum of symptoms. Most patients admitted to hospital exhibited fever (98%), chills/rigors (87%), cough (83%), shortness of breath (72%), and muscle pain (32%). A quarter of patients also experienced gastrointestinal symptoms, including diarrhoea and vomiting.

However, in contrast to SARS, the majority of cases (96%) occurred in people with underlying chronic medical conditions including diabetes (68%), high blood pressure (34%), chronic heart disease (28%), and chronic renal disease (49%).

"Despite sharing some clinical similarities with SARS (eg, fever, cough, incubation period), there are also some important differences such as the rapid progression to respiratory failure, up to 5 days earlier than SARS"*, explains Professor Ziad Memish, the Deputy Minister for Public Health from the Kingdom of Saudi Arabia, who led the research.

"In contrast to SARS, which was much more infectious especially in healthcare settings and affected the healthier and the younger age group, MERS appears to be more deadly with 60% of patients with co-existing chronic illnesses dying, compared with the 1-2% toll of SARS. Although this high mortality rate with MERS is probably spurious due to the fact that we are only picking up severe cases and missing a significant number of milder or asymptomatic cases, so far there is little to indicate that MERS will follow a similar path to SARS."*

According to co-author Professor Ali Zumla from University College London, "The recent identification of milder or asymptomatic cases of MERS in health care workers, children, and family members of contacts of MERS cases indicates that we are only reporting the tip of the iceberg of severe cases and there is a spectrum of milder clinical disease which requires urgent definition. Ultimately the key will be to identify the source of MERS infection, predisposing factors for susceptibility to infection, and the predictive factors for poor outcome. Meanwhile infection control measures within hospitals seem to work."*

Writing in a linked Comment, Professor Christian Drosten from the University of Bonn Medical Centre in Germany points to the urgent need for accurate diagnostic tests to help focus control efforts and minimise the risk of spread to others, "To ascertain relevant data for MERS epidemiology, we need to develop serological assays using samples from well defined groups of patients, such as described here. Population-based antibody testing could establish the extent of MERS-CoV infection, instead of only seeing the tip of the iceberg represented by cases admitted, such as those summarised in this important paper."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our infectious diseases / bacteria / viruses section for the latest news on this subject.

*Quotes direct from authors and cannot be found in text of Article.

The Lancet

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Lancet, The. "Fullest clinical report of Saudi MERS cases to date points to important differences with SARS." Medical News Today. MediLexicon, Intl., 26 Jul. 2013. Web.
27 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Fullest clinical report of Saudi MERS cases to date points to important differences with SARS'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Thursday, 25 July 2013

Promoting Clinical Trials MENA, 7-8 October 2013, Dubai, UAE

Main Category: Clinical Trials / Drug Trials
Article Date: 24 Jul 2013 - 8:00 PDT Current ratings for:
Promoting Clinical Trials MENA, 7-8 October 2013, Dubai, UAE
not yet ratednot yet rated

The global landscape for clinical trials has continued to evolve and change over the last ten years. One of the biggest changes has been the shift towards the emerging markets.

The MENA region is generally one of the fastest growing economies in the world, one of the industries enjoying this increase in demand is the clinical research sector. Key factors for this include a large treatment naïve population, the improvement of the healthcare infrastructure and the large number of therapeutic indications. There are of course key factors that need to be taken into account to ensure the trials are successful. Concerns such as political climate, culture differences, qualified data and the limited number of trained CRA's have traditionally deterred international pharmaceuticals from carrying out their research. Both CRO's and Sponsors will discuss how those challenges have not affected the successful running of their clinical development and to further explore the opportunities.

This conference is aiming to raise the profile as a key region to conduct clinical research with the recent investment in the local infrastructure. We will be bringing together a delegation that includes both international and local pharmaceutical companies, regulatory bodies, government officials and CRO's to improve and promote drug development.

Topics being addressed include:

Partnership Strategies to Strengthen Stakeholders Relationships The Important Role Technology Plays in Effective Clinical Trial Operations Addressing Challenges in Biologistic Quality and Cost Ensuring Global R&D Budgets Continue to grow in the region Strategies to Strengthen Patient Recruitment and Participation Best Practice for Site Selection and Investigator Meetings What Role Government is Playing to Promote the Region Improving the Operational Efficiency for Clinical Trials How to Ensure Trials Stay Cost Effective Tackling the Limited Number of CRAs and Training in the Region The Role Local Hospitals Play in Enhancing MENA as a Clinical Trials Hub

For further information please visit: http://www.promotingclinicaltrials.com

Article adapted by Medical News Today from original press release. Source: Qatalyst Global
Visit our clinical trials / drug trials section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Global, Qatalyst. "Promoting Clinical Trials MENA, 7-8 October 2013, Dubai, UAE." Medical News Today. MediLexicon, Intl., 24 Jul. 2013. Web.
24 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Promoting Clinical Trials MENA, 7-8 October 2013, Dubai, UAE'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here